Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B

Executive Summary

Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.

Advertisement

Related Content

Mehta Analysis: China, A Populist Pharma Power
1ST Bio Bets On BBB-Penetrating C-ABL Inhibitor As Potential Disease-Modifying Parkinson's Drug
A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas
Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
AbbVie Goes Boldly Into Immuno-Neurology With Alector
An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
VC-Run Dementia Discovery Fund Plays It Safe With First Investment
FINANCE ROUNDUP: Will VC Be Last Man Standing If Biotech Bubble Bursts?
Celgene diversifies with $7.2bn Receptos buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel